TY - JOUR
T1 - Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients
T2 - A feasibility study
AU - Maeda, Osamu
AU - Matsuoka, Ayumu
AU - Miyahara, Ryoji
AU - Funasaka, Kohei
AU - Hirooka, Yoshiki
AU - Fukaya, Masahide
AU - Nagino, Masato
AU - Kodera, Yasuhiro
AU - Goto, Hidemi
AU - Ando, Yuichi
N1 - Publisher Copyright:
© The Author(s) 2017. Published by Baishideng PublishingGroup Inc. All rights reserved.
PY - 2017
Y1 - 2017
N2 - AIM To evaluate the feasibility of chemotherapy including fluoropyrimidine, platinum and taxane with modified dosages for unresectable gastric cancer in Japanese patients. METHODS We performed a feasibility study of a modified docetaxel, cisplatin and capecitabine (DCX) regimen for stage ? gastric cancer. In particular, 30 or 40 mg/m2 of docetaxel on day 1, 60 mg/m2 of cisplatin on day 1, and 2000 mg/m2 of capecitabine for 2 wk were administered every three weeks. RESULTS Three patients were treated with modified DCX (mDCX) with 30 mg/m2 docetaxel, and five patients were treated with this regimen with 40 mg/m2 docetaxel. Grade 3 or 4 neutropenia was observed in six of the eight patients; no patients exhibited febrile neutropenia. Partial response was achieved in four of the eight patients. Three patients underwent gastrectomy, which achieved R0 resection without residual tumors in dissected lymph nodes. In one of these three patients, resected specimens revealed pathological complete response in the primary lesion and in lymph nodes. CONCLUSION mDCX was well tolerated by Japanese patients with stage ? gastric cancer. This regimen might be useful for allowing gastric cancer patients with distant lymph node metastasis to undergo conversion surgery.
AB - AIM To evaluate the feasibility of chemotherapy including fluoropyrimidine, platinum and taxane with modified dosages for unresectable gastric cancer in Japanese patients. METHODS We performed a feasibility study of a modified docetaxel, cisplatin and capecitabine (DCX) regimen for stage ? gastric cancer. In particular, 30 or 40 mg/m2 of docetaxel on day 1, 60 mg/m2 of cisplatin on day 1, and 2000 mg/m2 of capecitabine for 2 wk were administered every three weeks. RESULTS Three patients were treated with modified DCX (mDCX) with 30 mg/m2 docetaxel, and five patients were treated with this regimen with 40 mg/m2 docetaxel. Grade 3 or 4 neutropenia was observed in six of the eight patients; no patients exhibited febrile neutropenia. Partial response was achieved in four of the eight patients. Three patients underwent gastrectomy, which achieved R0 resection without residual tumors in dissected lymph nodes. In one of these three patients, resected specimens revealed pathological complete response in the primary lesion and in lymph nodes. CONCLUSION mDCX was well tolerated by Japanese patients with stage ? gastric cancer. This regimen might be useful for allowing gastric cancer patients with distant lymph node metastasis to undergo conversion surgery.
UR - http://www.scopus.com/inward/record.url?scp=85014538730&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014538730&partnerID=8YFLogxK
U2 - 10.3748/wjg.v23.i6.1090
DO - 10.3748/wjg.v23.i6.1090
M3 - Article
C2 - 28246483
AN - SCOPUS:85014538730
SN - 1007-9327
VL - 23
SP - 1090
EP - 1097
JO - World Journal of Gastroenterology
JF - World Journal of Gastroenterology
IS - 6
ER -